In addition, they demonstrated that the blockade of CTLA-4-mediated signaling during the stimulation of MBP-reactive T cells from healthy subjects increased proliferative and cytokine responses, whereas blocking CTLA-4 in MS patients had fewer effects [76]. This evidence concerns the gene CTLA4 and myeloid sarcoma.